Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity

[1]  T. Leanderson,et al.  Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse , 2018, PloS one.

[2]  C. Wegner,et al.  Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis , 2017, Acta Neuropathologica.

[3]  Qinghua Jiang,et al.  Genetic variant rs763361 regulates multiple sclerosis CD226 gene expression , 2017, Proceedings of the National Academy of Sciences.

[4]  Ignacio S. Caballero,et al.  Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor , 2016, Proceedings of the National Academy of Sciences.

[5]  T. Leanderson,et al.  Erratum to: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth , 2016, BMC Cancer.

[6]  R. Hohlfeld,et al.  Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation , 2016, Proceedings of the National Academy of Sciences.

[7]  T. Leanderson,et al.  The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth , 2016, BMC Cancer.

[8]  T. Leanderson,et al.  Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment , 2015, Journal of Immunotherapy for Cancer.

[9]  R. Germain,et al.  NK-DC crosstalk controls the autopathogenic Th 17 response through an innate IFN-– IL-27 axis , 2015 .

[10]  Z. Qiu,et al.  CD226 gene polymorphisms are associated with non-small-cell lung cancer in the Chinese Han population , 2015, Therapeutics and clinical risk management.

[11]  F. Souza-Fonseca-Guimaraes,et al.  DNAM-1 expression marks an alternative program of NK cell maturation. , 2015, Cell reports.

[12]  M. Smyth,et al.  Balancing natural killer cell activation through paired receptors , 2015, Nature Reviews Immunology.

[13]  L. Ellis,et al.  Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models , 2014, Cancer Immunology Research.

[14]  L. Lanier,et al.  Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. , 2014, Immunity.

[15]  M. Mcgrath,et al.  Cutting Edge: DNAX Accessory Molecule 1–Deficient CD8+ T Cells Display Immunological Synapse Defects That Impair Antitumor Immunity , 2014, The Journal of Immunology.

[16]  P. Basse,et al.  NK cells in the tumor microenvironment. , 2014, Critical reviews in oncogenesis.

[17]  H. Kohrt,et al.  Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor , 2013, Proceedings of the National Academy of Sciences.

[18]  T. Leanderson,et al.  Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: reduced priming of proinflammatory effector CD4(+) T cells. , 2013, The American journal of pathology.

[19]  F. Zipp,et al.  Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. , 2013, Brain : a journal of neurology.

[20]  F. Paul,et al.  Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation , 2013, Journal of Neuroimmunology.

[21]  E. Ullrich,et al.  The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions? , 2012, Current medicinal chemistry.

[22]  R. Sobel,et al.  Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity , 2012, PloS one.

[23]  T. Waldmann,et al.  Intrathecal effects of daclizumab treatment of multiple sclerosis , 2011, Neurology.

[24]  D. Maric,et al.  Unexpected Role for Granzyme K in CD56bright NK Cell-Mediated Immunoregulation of Multiple Sclerosis , 2011, The Journal of Immunology.

[25]  Javier Martín,et al.  A 3'-untranslated region variant is associated with impaired expression of CD226 in T and natural killer T cells and is associated with susceptibility to systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[26]  H. Ljunggren,et al.  Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome , 2010, Leukemia.

[27]  F. Shi,et al.  Central nervous system (CNS)–resident natural killer cells suppress Th17 responses and CNS autoimmune pathology , 2010, The Journal of experimental medicine.

[28]  G. Weiner,et al.  Rituximab: mechanism of action. , 2010, Seminars in hematology.

[29]  Johan Vallon-Christersson,et al.  Open Access Research , 2022 .

[30]  M. Colonna,et al.  DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases , 2009, The Journal of Immunology.

[31]  H. Ljunggren,et al.  Down-regulating Dnam-1 on Nk Cells Cd155 Impair Tumor Targeting by Primary Human Tumor Cells Expressing , 2022 .

[32]  A. Chan,et al.  Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients , 2009, Genes and Immunity.

[33]  E. Kremmer,et al.  Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK‐mediated killing of immature dendritic cells , 2009, Journal of leukocyte biology.

[34]  J. Lünemann,et al.  Regulatory NK-Cell Functions in Inflammation and Autoimmunity , 2009, Molecular medicine.

[35]  D. Schadendorf,et al.  NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. , 2009, The Journal of clinical investigation.

[36]  M. Colonna,et al.  DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors , 2008, The Journal of experimental medicine.

[37]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[38]  A. Flügel,et al.  A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. , 2008, The Journal of clinical investigation.

[39]  H. Young,et al.  In Vivo Regulation of Experimental Autoimmune Encephalomyelitis by NK Cells: Alteration of Primary Adaptive Responses12 , 2008, The Journal of Immunology.

[40]  Bernhard Hemmer,et al.  Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. , 2007, Brain : a journal of neurology.

[41]  K. Wucherpfennig,et al.  Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. , 2007, Immunity.

[42]  V. Kuchroo,et al.  Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. , 2006, The Journal of clinical investigation.

[43]  Steffen Jung,et al.  The FASEB Journal • Research Communication The neuronal chemokine CX3CL1/fractalkine , 2022 .

[44]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Smyth,et al.  CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity1 , 2006, The Journal of Immunology.

[46]  T. Tabira,et al.  Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.

[47]  T. Yamamura,et al.  The regulatory role of natural killer cells in multiple sclerosis. , 2004, Brain : a journal of neurology.

[48]  D. Paty,et al.  Clinical relapses of multiple sclerosis are associated with ‘novel’ valleys in natural killer cell functional activity , 2003, Journal of Neuroimmunology.

[49]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[50]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[51]  R. Smeltz,et al.  Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. , 1999, Journal of immunology.

[52]  H. Lassmann,et al.  B Lymphocytes Producing Demyelinating Autoantibodies: Development and Function in Gene-targeted Transgenic Mice , 1998, Journal of Neuroimmunology.

[53]  K. Kohyama,et al.  Role of natural killer cells and TCRγ δ T cells in acute autoimmune encephalomyelitis , 1998 .

[54]  T. Tabira,et al.  Regulation of Experimental Autoimmune Encephalomyelitis by Natural Killer (NK) Cells , 1997, The Journal of experimental medicine.

[55]  Y. Suzuki,et al.  Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. , 1998, European journal of immunology.

[56]  T. Mcclanahan,et al.  DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.

[57]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.

[58]  I. Fidler.  Biological behavior of malignant melanoma cells correlated to their survival in vivo. , 1975, Cancer research.

[59]  David Gottlieb,et al.  Mechanism of Action , 2012, Antibiotics.